ReviewMolecular biology reports2026
Molecular mechanisms of cardioprotection: biomarkers, signaling pathways, and emerging molecular signatures in cardiovascular disease.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) are the leading cause of worldwide mortality, with myocardial infarction (MI) being one of the most significant clinical indicators. Around 85% of the 17.9 million cardiovascular deaths are due to heart attack and stroke. This comprehensive review focuses on cardiac biomarkers and cardioprotection signaling pathways. This review describes key cardioprotective signaling pathways, including PKCε, RISK (Reperfusion Injury Salvage Kinase), MAPK, NO/cGMP/PKG, and SAFE (Survivor Activating Factor Enhancement), which work together to regulate cardiovascular functions, prevent cellular death, and maintain mitochondrial stability. The physiology of heart injury is examined through the complex interactions of inflammatory processes, necrotic transmissions, self-destruction, and oxidative stress, with particular attention to mitochondrial dysfunction, reactive oxygen species (ROS), and NLRP3 inflammasome activation. A thorough review of traditional and innovative cardiac biomarkers is provided, including long non-coding RNAs, microRNAs (e.g., miR-21, miR-486-5p, miR-126), creatine kinase-MB (CK-MB), cardiac troponins (cTnI/cTnT), inflammatory markers (CRP, IL-6, TNF-α), and natriuretic peptides (BNP/NT-pro BNP). A broad discussion of these novel biomarkers covers their applications in prognosis, screening, and medical assessment, emphasizing their roles in risk evaluation, early detection, and personalized therapy plans. This study offers an extensive perspective on cardiac protection, integrating clinical applications with physiological mechanisms to promote precise cardiovascular treatment and improve patient outcomes.
Indexed as
Identifiers
42886397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.